The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review

被引:71
作者
Fond, Guillaume [1 ,2 ,3 ]
d'Albis, Marc-Antoine [1 ,2 ,3 ]
Jamain, Stephane [1 ,2 ,3 ]
Tamouza, Ryad [4 ,5 ]
Arango, Celso [6 ]
Fleischhacker, W. Wolfgang [7 ]
Glenthoj, Birte [8 ,9 ]
Leweke, Markus [10 ]
Lewis, Shon [11 ]
McGuire, Phillip [12 ]
Meyer-Lindenberg, Andreas [10 ]
Sommer, Iris E. [13 ]
Winter-van Rossum, Inge [13 ]
Kapur, Shitij [14 ]
Kahn, Rene S. [13 ]
Rujescu, Dan [15 ]
Leboyer, Marion [1 ,2 ,3 ]
机构
[1] Hop Henri Mondor, INSERM, U955, Eq Psychiat Genet & Psychopathol 15, F-94010 Creteil, France
[2] Univ Paris Est Creteil, DHU Pe PSY, Pole Psychiat, Hop Univ H Mondor, Creteil, France
[3] Fdn FondaMental, Creteil, France
[4] Hop St Louis, Jean Dausset Lab, Paris, France
[5] Hop St Louis, INSERM, UMRS 940, Paris, France
[6] Univ Complutense, Hosp Gen Univ Gregorio Maranon, Child & Adolescent Psychiat Dept, IiSGM,Sch Med,CIBERSAM, E-28040 Madrid, Spain
[7] Med Univ Innsbruck, Dept Psychiat & Psychotherapy, A-6020 Innsbruck, Austria
[8] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Neuropsychiat Schizophrenia Res, DK-1168 Copenhagen, Denmark
[9] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Clin Intervent & Neuropsychiat Schizophrenia, Psychiat Hosp Ctr Glostrup, DK-1168 Copenhagen, Denmark
[10] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Mannheim, Germany
[11] Univ Manchester, Inst Brain Behav & Mental Hlth, Manchester, Lancs, England
[12] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London WC2R 2LS, England
[13] UMC Utrecht, Brain Ctr Rudolf Magnus, Dept Psychiat, Utrecht, Netherlands
[14] Kings Coll London, Inst Psychiat, London WC2R 2LS, England
[15] Univ Halle Wittenberg, Dept Psychiat, D-06108 Halle, Germany
基金
英国医学研究理事会;
关键词
biomarker; first-episode psychosis; antipsychotic response; pharmacogenetic; inflammation; oxidative stress; hormonal; cortisol; 1ST EPISODE SCHIZOPHRENIA; CORTISOL AWAKENING RESPONSE; PLACEBO-CONTROLLED-TRIAL; DRUG-NAIVE PATIENTS; INDUCED WEIGHT-GAIN; DECREASED GLUTATHIONE LEVELS; POLYUNSATURATED FATTY-ACIDS; RECEPTOR GENE POLYMORPHISM; RECENT-ONSET SCHIZOPHRENIA; EARLY-PHASE SCHIZOPHRENIA;
D O I
10.1093/schbul/sbv002
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Successful treatment of first-episode psychosis is one of the major factors that impacts long-term prognosis. Currently, there are no satisfactory biological markers (biomarkers) to predict which patients with a first-episode psychosis will respond to which treatment. In addition, a non-negligible rate of patients does not respond to any treatment or may develop side effects that affect adherence to the treatments as well as negatively impact physical health. Thus, there clearly is a pressing need for defining biomarkers that may be helpful to predict response to treatment and sensitivity to side effects in first-episode psychosis. The present systematic review provides (1) trials that assessed biological markers associated with antipsychotic response or side effects in first-episode psychosis and (2) potential biomarkers associated with biological disturbances that may guide the choice of conventional treatments or the prescription of innovative treatments. Trials including first-episode psychoses are few in number. Most of the available data focused on pharmacogenetics markers with so far only preliminary results. To date, these studies yielded-beside markers for metabolism of antipsychotics-no or only a few biomarkers for response or side effects, none of which have been implemented in daily clinical practice. Other biomarkers exploring immunoinflammatory, oxidative, and hormonal disturbances emerged as biomarkers of first-episode psychoses in the last decades, and some of them have been associated with treatment response. In addition to pharmacogenetics, further efforts should focus on the association of emergent biomarkers with conventional treatments or with innovative therapies efficacy, where some preliminary data suggest promising results.
引用
收藏
页码:559 / 573
页数:15
相关论文
共 144 条
  • [1] Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis
    Aas, M.
    Dazzan, P.
    Mondelli, V.
    Toulopoulou, T.
    Reichenberg, A.
    Di Forti, M.
    Fisher, H. L.
    Handley, R.
    Hepgul, N.
    Marques, T.
    Miorelli, A.
    Taylor, H.
    Russo, M.
    Wiffen, B.
    Papadopoulos, A.
    Aitchison, K. J.
    Morgan, C.
    Murray, R. M.
    Pariante, C. M.
    [J]. PSYCHOLOGICAL MEDICINE, 2011, 41 (03) : 463 - 476
  • [2] Antibodies to infectious agents in individuals at ultra-high risk for psychosis
    Amminger, G. Paul
    McGorry, Patrick D.
    Berger, Gregor E.
    Wade, Darryl
    Yung, Alison R.
    Phillips, Lisa J.
    Harrigan, Susy M.
    Francey, Shona M.
    Yolken, Robert H.
    [J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (10) : 1215 - 1217
  • [3] Update on Omega-3 Polyunsaturated Fatty Acids in Early-Stage Psychotic Disorders
    Amminger, G. Paul
    McGorry, Patrick D.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2012, 37 (01) : 309 - 310
  • [4] Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial
    Amminger, G. Paul
    Schafer, Miriam R.
    Papageorgiou, Konstantinos
    Klier, Claudia M.
    Cotton, Sue M.
    Harrigan, Susan M.
    Mackinnon, Andrew
    McGorry, Patrick D.
    Berger, Gregor E.
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2010, 67 (02) : 146 - 154
  • [5] Reduced antioxidant defense in early onset first-episode psychosis: a case-control study
    Antonio Mico, Juan
    Olga Rojas-Corrales, Maria
    Gibert-Rahola, Juan
    Parellada, Mara
    Moreno, Dolores
    Fraguas, David
    Graell, Montserrat
    Gil, Javier
    Irazusta, Jon
    Castro-Fornieles, Josefina
    Soutullo, Cesar
    Arango, Celso
    Otero, Soraya
    Navarro, Ana
    Baeza, Inmaculada
    Martinez-Cengotitabengoa, Monica
    Gonzalez-Pinto, Ana
    [J]. BMC PSYCHIATRY, 2011, 11
  • [6] Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients
    Arranz, B
    Rosel, P
    Ramírez, N
    Dueñas, R
    Fernández, P
    Sanchez, JM
    Navarro, MA
    San, L
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (10) : 1335 - 1342
  • [7] Psychopathology in first-episode schizophrenia and antibodies to Toxoplasma gondii
    Bachmann, S
    Schröder, J
    Bottmer, C
    Torrey, EF
    Yolken, RH
    [J]. PSYCHOPATHOLOGY, 2005, 38 (02) : 87 - 90
  • [8] Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients
    Baeza, Immaculada
    Castro-Fornieles, Josefina
    Deulofeu, Ramon
    de la Serna, Elena
    Goti, Javier
    Salva, Joan
    Bernardo, Miquel
    [J]. PSYCHIATRY RESEARCH, 2009, 168 (02) : 110 - 118
  • [9] Bartecek R, 2012, NEUROENDOCRINOL LETT, V33, P236
  • [10] Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial
    Berger, Gregor E.
    Proffitt, Tina-Marie
    McConchie, Mirabel
    Yuen, HokPan
    Wood, Stephen J.
    Amminger, G. Paul
    Brewer, Warrick
    McGorry, Patrick D.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (12) : 1867 - 1875